
JCR Pharmaceuticals Completes Enrollment for JR-141 Phase III Trial
JCR Pharmaceuticals Co., Ltd. announced that it achieved the enrollment of the target number of participants in the global Phase III clinical trial of JR-141
JCR Pharmaceuticals Co., Ltd. announced that it achieved the enrollment of the target number of participants in the global Phase III clinical trial of JR-141
A refreshed global brand signals JCR’s expanded international presence and unwavering focus on rare and genetic diseases worldwide JCR Pharmaceuticals Co., Ltd. a global specialty
Fuel up with free Health Tech Insights